Baptist Health Miami Cancer Institute Research Mayo Clinic Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center MD Anderson Cancer Center UC College of Medicine Memorial Healthcare System Penn Precision Med City of Hope ASCO JCO Precision Oncology Dana-Farber What a treat it has been listening to groundbreaking studies Vivek Subbiah, MD MD Anderson Cancer Center Luis Diaz Memorial Sloan Kettering Cancer Center Tanios Bekaii-Saab, MD Jenny C. Chang Tom Herzog UC College of Medicine in the first session of #MCIprecisionmedicine Miami Cancer Institute Research Baptist Health

Stephen V Liu, MD JCO Precision Oncology Nathan A. Pennell MD, PhD, FASCO Great results! I wonder if we would see the same benefit for early stage lung cancers… 🤔

Authors Antoinette Tan, MD, FACP & Neelam Desai from Levine Cancer Institute, Atrium Health sum up key data of ICI and PARP inhibitors for high-risk, early-stage breast cancer ➡️ fal.cn/3yHXz #bcsm

New article published w/ HSL MedOnc Fellows Nildevande Firmino Marcelo Queiroz Denis Jardim & Sírio-Libanês team. Impressive response to sequential #HER2 🎯 therapy in M+ HER2- amplified #bladdercancer . Check it out at JCO Precision Oncology! ascopubs.org/doi/pdf/10.120…

This #JCOPO review articles summarizes recent advances in precision medicine & #immunotherapy that are likely to reshape the treatment landscape for #cholangiocarcinoma in the coming years:
➡️ fal.cn/3yGY3 #ImmunoOnc

🔥TP53 Gain-of-Function & Non–Gain-of-Function Mutations Are Associated With Differential Prognosis in #PDAC 🔥
JCO Precision Oncology
doi.org/10.1200/PO.22.…
🔎RWD 893 pts
👇Differential impact of TP53, KRAS, CDKN2A & SMAD4 SNVs on OS
🧐GOF mutp53 & mutKRAS/mutCDKN2A -> worse prognosis…

Our new work 'Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma' led by Amanda Marinoff (UCSF Benioff SF), Katie Janeway (@DanaFarber), myself, & collaborators is out now JCO Precision Oncology
ascopubs.org/doi/full/10.12…

Ed Esplin, MD, PhD Rafeh Naqash, MD Heather Hampel JCO Precision Oncology CGA-IGC OncoAlert Keep at it Ed. Great work.

A team of FLORIDA researchers led by Jatinder Lamba, Ph.D., of FLORIDAPharmacy has created a way to use genetics to predict leukemia patients’ risk for complications from chemotherapy drug toxicity. The study was published in JCO Precision Oncology.

Read more 👉 go.ufl.edu/9120ard

^^ Critical need for implementation of #Universal #Germline #Genetictesting discussed by Heather Hampel Ed Esplin, MD, PhD moderated by Rafeh Naqash, MD JCO Precision Oncology
sites.libsyn.com/427415/site/un…

Study describing validation of a prognostic six-miRNA signature risk by Nuttapong Ngamphaiboon et al from theTCGA database, which categorized patients w/ locally advanced head & neck squamous cell carcinoma (LA-HNSCC) into low-risk and high-risk groups ➡️ fal.cn/3yHBn #hncsm

Extremely honored for our paper to be included among those outstanding papers and amazing authors!!
Many thanks to the team at ASCO #JCOPO JCO Precision Oncology for this opportunity and for publishing our research!! OncoAlert Levine Cancer Institute

⭐ #JCOPO published outstanding articles in 2022. Check out the top 5! ➡️ fal.cn/3vS6d

Authors include: Mohamed E. Salem, MD Alexander Drilon MD Ed Esplin, MD, PhD

🔵 This is a really noteworthy podcast with important data about expanding germline genetic testing indications!

🔴 I strongly recommend this episode!

JCO Precision Oncology
Heather Hampel Ed Esplin, MD, PhD 👏🏻👏🏻

We conclude that genomic tumor complexity is an independent prognostic biomarker and that de-escalation of adjuvant imatinib treatment should be explored in patients with cytogenetically simple GISTs.
Oslounivsykehus Norwegian Sarcoma Group Helse Sør-Øst RHF #gist #sarcoma JCO Precision Oncology

Study by Kaiser Permanente Research NorCal et at. in patients w/ #PancreaticCancer : TP53 GOF was associated w/substantially worse prognosis of KRAS mutation versus wild-type KRAS, primarily driven by the subgroup of patients who also bore CDKN2A mutation. ➡️ fal.cn/3yHpV #pancsm

💫🌟Human organs-on-chips for disease modelling, drug development and personalized medicine by Dr Donald Ingber🌟💫
#personalizedmedicine
JCO Precision Oncology Nature Medicine
OncoAlert
OncoReporte
Harvard Medical School nature.com/articles/s4157…

Shoutout to Dr. Andrew Hendifar Sam Klempner among 1st cases of an acquired TMZ-induced, truncating MSH6 mut resulting in high #TMB w/durable response to #PD -1 in high-grade #NEN JCO Precision Oncology pubmed.ncbi.nlm.nih.gov/35050748/ Cancer at Cedars-Sinai #TumorBoardTuesday

Stephen V Liu, MD JCO Precision Oncology Nathan A. Pennell MD, PhD, FASCO Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study
sciencedirect.com/science/articl…

We've collected the most common vintage items that collectors are paying top dollar for. If you're lucky enough to have any of these, consider yourself rich.

Last call! ⌚ Early career? Interested in publishing? 🤝 Register for one-on-one mentoring in the ASCO Publications Lounge at #ASCO23 ! Sign up closes 11:59pm ET TODAY May 26. ➡️ fal.cn/3yzPU

🎧 Listen now!

In this JCO PO Conversations podcast episode, host Rafeh Naqash, MD speaks with Dr. Edward Esplin & Prof. Heather Hampel, who discuss their latest #JCOPO article ➡️ fal.cn/3vVQA

#TumorBoardTuesday Rachel Riechelmann Mike Pishvaian Johnathan Ebben MD, PhD Pamela Kunz, MD Mark Lewis Diane Reidy-Lagunes Timothy M. Pawlik Can.Heal Duilio Rocha Filho Renata D'Alpino Daniel Bulzico Juan OConnor Mariano Dioca Thor Halfdanarson Heloisa Soares MD Ricardo Carvalho Mauro DS Donadio Gil-Santana Manik Amin Chirayu Mohindroo,MD Carla Cavalcanti Dr Joseph McCollom DO Jp Solar Vasconcelos Antonio Torres Let's Win Pancreatic Cancer 💜 6/15 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 2👩🏻‍🏫

📌MSI biomarker
📍≤ 10% of neuroendocrine carcinoma
📍MSI & TMB-h rare in G3 (<1%)
📍Hypermutation may be induced by temozolamide in #gliomas and #NETCancer
📍Molecular profiling upon DP on alkylating agents may find TMB-h

🔥Precision Medicine & Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals & Ongoing Clinical Trials🔥
JCO Precision Oncology
doi.org/10. 1200/PO.22.00573
👏Excellent summary
🤩druggable🎯in 40-50% of cases
🤩2 pos. phs-III for IO
ESMO - Eur. Oncology…